• Leukemias, lymphomas, and other hematologic cancers

Yescarta Generic Name & Formulations

General Description

Axicabtagene ciloleucel (contains max of 2×108 CAR-positive viable T cells); per infusion bag; cell susp for IV infusion; contains dimethyl sulfoxide (DMSO) and albumin (human).

Pharmacological Class

CD19-directed genetically modified autologous T cell immunotherapy.

How Supplied

Infusion bag (approx. 68mL)—1


Generic Availability


Yescarta Indications


In adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. In adults with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. In adults with relapsed or refractory follicular lymphoma (FL) after 2 or more lines of systemic therapy.

Limitations of Use

Not for treating primary CNS lymphoma.

Yescarta Dosage and Administration


For autologous and IV use only; confirm patient identity prior to infusion. Do not use a leukodepleting filter. Give lymphodepleting chemotherapy (cyclophosphamide 500mg/m2 IV + fludarabine 30mg/m2 IV) on the 5th, 4th, and 3rd days prior to Yescarta infusion. Premedicate with APAP and diphenhydramine approx. 60mins prior to Yescarta infusion. Consider use of prophylactic corticosteroids after weighing benefits/risks. Infuse contents of bag within 30mins. Target dose: 2×106 CAR-positive viable T cells/kg; max 2×108 CAR-positive viable T cells. Management of severe adverse reactions: see full labeling.


Not established.

Yescarta Contraindications

Not Applicable

Yescarta Boxed Warnings

Boxed Warning

Cytokine release syndrome (CRS). Neurologic toxicities.

Yescarta Warnings/Precautions


Risk of CRS; do not give to patients with active infection and/or inflammatory disorders. Have tocilizumab and emergency equipment readily available. Monitor at least daily for 7 days at the healthcare facility following infusion for signs/symptoms of CRS and neurologic toxicities. Continue to monitor for CRS for 4 weeks after infusion; at 1st sign, provide supportive care, tocilizumab and/or corticosteroids as indicated. Monitor for neurologic toxicities for 4 weeks after infusion and treat promptly. Monitor for infection, febrile neutropenia; evaluate, manage and treat appropriately. Screen for HBV, HCV, and HIV prior to cell collection for manufacturing. Monitor blood counts (prior to and after initiation), immunoglobulin levels after treatment. Pregnancy: not recommended. Verify pregnancy status prior to initiation. Nursing mothers.



Yescarta Pharmacokinetics

See Literature

Yescarta Interactions


Concomitant live virus vaccines: not recommended for ≥6 weeks prior to lymphodepleting chemotherapy, during Yescarta treatment, and until immune recovery.

Yescarta Adverse Reactions

Adverse Reactions

CRS, fever, hypotension, encephalopathy, tachycardia, fatigue, headache, decreased appetite, chills, diarrhea, febrile neutropenia, infections-pathogen unspecified, nausea, hypoxia, tremor, musculoskeletal pain, cough, vomiting, dizziness, constipation, cardiac arrhythmias; hypersensitivity reactions, hypogammaglobulinemia, neurologic toxicities, prolonged cytopenias, secondary malignancies (monitor).

Yescarta Clinical Trials

See Literature

Yescarta Note


Available only through a restricted REMS Program. For more information visit or call (844) 454-5483.

Yescarta Patient Counseling

See Literature